The Peptide Field Guide

Appetite regulation, blood glucose control, reduction of food-noise signaling. The most-studied GLP-1 RA with extensive Phase III data.

GI effects (nausea, diarrhea) are dose-dependent. Thyroid C-cell signals in rodent models. Slow titration is standard in research protocols.

Start at the lowest reference dose and titrate up over weeks. Research protocols typically run once-weekly subcutaneous administration.

Greater weight reduction than single-agonist GLP-1s in head-to-head trials (~21-22% vs ~15%). Dual incretin action may offer improved GI tolerability and bone-protective signaling.

Vision changes reported in a subset of trial participants. Mood and affect changes warrant monitoring in any research protocol.

Often selected over semaglutide when GI tolerance is a priority in the research design.

Phase II data showed ~24-29% body weight reduction and significant hepatic fat clearance. The glucagon receptor adds caloric expenditure on top of appetite suppression.

Resting heart rate elevation of up to 10-15 BPM observed in some cohorts. Not yet FDA approved — research compound only.

The most-watched metabolic research peptide of 2026. Triple-agonist mechanism represents a new generation beyond dual-agonists.

Targets adipose tissue lipolysis without triggering GH-related blood glucose or IGF-1 elevation. Studied as a fat-loss-specific HGH fragment.

Tachyphylaxis is well-documented — effectiveness drops significantly after 2-4 weeks of continuous use.

Research protocols typically cycle 2 weeks on, 4 weeks off. Not effective when used daily long-term without breaks.

Sustained GH elevation, improved sleep quality, and recovery markers. The DAC variant extends half-life; No-DAC produces sharper GH pulses.

Water retention can elevate blood pressure. Facial flushing is common after administration.

Most effective when stacked with Ipamorelin — the GHRH + GHRP combination produces significantly stronger GH pulses than either compound alone.

Clean GH pulse without cortisol or prolactin elevation — the most selective of the GHRPs studied to date.

Limited effect when used alone. Best results in research protocols that pair it with a GHRH compound.

Often called "the gold standard GHRP" for its selectivity. Stack with CJC-1295 for meaningfully stronger GH output.

Gentle GH support, improved sleep architecture. The mildest of the GHRHs, often used as a first-line research reference.

Least potent of the GHRH analogs — lower reward alongside lower risk profile.

Recommended starting point in protocols where the researcher is new to GH secretagogues.

Most targeted GHRH for visceral/abdominal fat reduction. FDA-approved for HIV-associated lipodystrophy — the only GHRH with that distinction.

Expensive. Long-term use can reduce insulin sensitivity and elevate blood glucose.

Best suited for research protocols specifically targeting abdominal fat distribution.

GHRP-6 is notable for extreme hunger stimulation — studied in hard-gainer research contexts. Both produce robust GH pulses.

Both elevate cortisol and prolactin. GHRP-6 in particular can affect libido and hormonal balance with extended use.

Require lab monitoring of cortisol and prolactin levels. Largely superseded by Ipamorelin in modern research protocols.

Oral GH boost without injections. Raises IGF-1 levels. Accessible entry point for GH research.

Significant water retention ("moon face"). Can push blood glucose to pre-diabetic ranges. Carbohydrate management is critical.

The only non-injectable option in this category. Blood glucose monitoring is essential in any protocol using this compound.

Hyperplasia (new muscle cell creation) — goes beyond what GH alone can achieve. Produces intense muscular effects at higher reference doses.

Can grow organs and accelerate pre-cancerous tissue. Hypoglycemia risk. Absolutely contraindicated with any cancer history.

High-risk, high-reward research compound. Not appropriate for researchers without significant prior experience in GH-pathway compounds.

Theoretically removes the genetic ceiling on muscle growth by blocking myostatin. The concept is compelling; real-world research data is mixed.

Significant fatigue reported. Expensive. Unknown long-term cardiac effects from chronic myostatin inhibition.

The gap between theoretical potential and observed research results is wider here than with most peptides.

Testosterone support, spermatogenesis maintenance, and testicular function preservation in research models.

Requires monitoring — not a simple supplement. Aromatization to estrogen is possible at higher doses.

The primary research tool for testosterone-pathway optimization. Often studied alongside TRT protocols.

Tendon and ligament repair, gut mucosal healing, inflammation reduction. The most consistently studied tissue-repair peptide in the literature. Often called "The Wolverine Peptide."

Theoretical angiogenesis concern (promotes blood vessel growth). Some researchers report emotional blunting (anhedonia) with extended use.

For structural injuries, local injection near the site is preferred. For GI research, oral administration is the standard protocol.

Systemic anti-inflammatory with flexibility and mobility benefits. Best suited when the research target is inflammation rather than structural damage.

Shorter half-life than older formulations — may require more frequent dosing in sustained protocols.

Systemic peptide — injection site is less important than with BPC-157 since it travels to inflammation sites. Often stacked with BPC-157 for complementary mechanisms.

Skin regeneration, hair follicle signaling, scar reduction, wound healing. Research suggests it resets expression of 4,000+ genes toward a younger state.

Injections can be painful. Overdosing disrupts copper/zinc balance and can cause persistent fatigue.

Dose precision matters — copper/zinc homeostasis is the limiting factor. Do not exceed reference ranges.

Anti-inflammatory potency comparable to steroids without steroidal side effects. Studied in IBS, Crohn's, and psoriasis research models.

Relatively new compound — long-term human data is still accumulating.

Worth considering in autoimmune and inflammatory research protocols before escalating to steroidal compounds.

Small fiber neuropathy repair. Targets burning, tingling, and nerve pain from diabetes or injury — repair rather than symptom masking.

Expensive. Requires 4-8 week cycles before meaningful results appear in research models.

Patience is required — this compound targets nerve repair timelines, which are inherently slow.

Deep focus, memory consolidation, brain fog reduction. Neuroprotective properties studied in stroke-prevention research. Upregulates BDNF expression.

Hair loss reported even in individuals without genetic predisposition. Contraindicated with seizure history.

Best administered in the morning — it is stimulating and will disrupt sleep if taken in the evening. Nasal delivery is standard.

Anxiolytic without sedation or cognitive impairment. Studied in high-stress, public-speaking, and performance-anxiety research models.

Higher doses can cause emotional dulling and flat affect. Dose-response curve has a ceiling.

Works by removing noise, not by adding a feeling. Researchers should not expect a perceptible "high" — the effect is subtractive.

Extremely potent nootropic — active at picomolar concentrations. Studied for cognitive decline and neurodegenerative research models.

Very limited human data. Potency at picomolar doses means dosing errors carry outsized consequences.

Research-only compound in the truest sense. Requires extreme precision in preparation and administration protocols.

Deeper delta-wave (restorative) sleep phases. Also studied in chronic pain and opiate-withdrawal research models.

Response is highly variable — some subjects show dramatic improvement, others none. Unpredictable even at high reference doses.

Administer 30-60 minutes before the target sleep window. Not for daytime use or operation of equipment.

Telomere lengthening via telomerase activation. Improved sleep cycle regulation and circadian markers. Sometimes called the "Fountain of Youth" peptide.

Expensive. Long-term human data is still largely observational. Theoretical concern about growing active cancer cells via telomerase upregulation.

Research protocols typically use short burst cycles (10-20 days) once or twice per year rather than continuous administration.

Central nervous system mechanism for sexual response — works through the brain, not blood flow like PDE5 inhibitors. FDA-approved as Vyleesi for hypoactive sexual desire disorder.

Nausea in 30-40% of first-time use. Blood pressure elevation with repeated dosing. Timing is unpredictable — onset can range from 1-5 hours.

Test with a small dose first. Frequency should not exceed 8x per month in research protocols. Plan for unpredictable onset timing.

Emotional intimacy, trust, relational depth. Often called the "connection peptide" — its effects are relational rather than mechanical.

Amplifies existing emotional states — if the baseline is volatile, oxytocin can intensify negative emotions as easily as positive ones.

Injectable form produces stronger effects than nasal spray, though nasal has faster onset. This is not a performance compound — it modulates emotional context.

Exercise mimetic encoded in mitochondrial DNA. Studied for endurance, fat burning, and glucose metabolism. Prevents fat gain on high-fat diets in research models.

High doses can cause anaphylactic-type reactions — start conservatively. Contraindicated in subjects with low blood sugar.

Best studied on training days. Research protocols typically cycle 2 months on, 2-3 months off. Avoid continuous use without breaks.

Targets mitochondrial inner membrane directly. Studied for chronic fatigue, overtraining recovery, and genuine energy capacity (not stimulant energy).

Expensive and harder to source than most peptides. Results require full 4-8 week cycles.

This is capacity building, not a stimulant spike. Research subjects should not expect stimulant-like onset.

Immune optimization and autoimmune regulation. Amplifies immune response where needed, calms it where overactive. FDA-approved in some countries for hepatitis B/C.

Expensive. Do not combine with immunosuppressant drugs without direct oversight from a qualified researcher.

Best used strategically — during travel, high-exposure periods, or post-illness recovery phases in research protocols.